Prevent cancer preclinical drug development program: toxicology and pharmacology testing
Active Awarded Last action
- Contract number
- 75N91024D00002
- Awardee
-
University Of Illinois UEI W8XEAJDKMXH3 Part of University Of Illinois
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- Prevent IDIQ mato RFP Pre-Solicitation · 75N91023R00024 · Posted Dec 19, 2022
- Last date to order 55% complete
- IDV ceiling
- $149,995,000.00
- Maximum order
- $149,995,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The University of Illinois, doing business as The Board of Trustees of the University of Illinois, was awarded an Indefinite Delivery Contract (IDC) valued at $149,995,000 from the National Cancer Institute (NCI) to support the PREVENT Cancer Preclinical Drug Development Program. This multiple-award contract aims to provide a structured approach to the development of cancer drugs and vaccines from discovery through clinical trials. The contract is divided into three separate pools: evaluating the efficacy and biomarkers of cancer prevention regimens, preclinical product development and Good Manufacturing Practice (GMP) manufacturing support for candidate cancer prevention vaccines, and assessing the pharmacological and toxicological effects of preventative agents. Through this IDC, the University of Illinois will compete for task orders to advance cancer prevention research and drug development efforts for the NCI.
The original solicitation described the overall objective of the PREVENT Cancer Preclinical Drug Development Program as providing a structured approach to drug and vaccine development, from discovery to the clinic. The contract was awarded without any set-aside designation, allowing the University of Illinois to serve as a prime contractor. The IDC has an ultimate completion date of January 24, 2029, providing the NCI with access to the University's extensive research capabilities and technical expertise in biomedical research, engineering, and related disciplines to support the development of innovative cancer prevention solutions.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91024D00002?
75N91024D00002 was awarded to University Of Illinois by National Cancer Institute (National Institutes of Health) on January 25, 2024.
How much is contract 75N91024D00002 worth?
75N91024D00002's own ceiling is $149,995,000. A single order can be worth up to $149,995,000.
Who can order from contract 75N91024D00002?
75N91024D00002 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N91024D00002 part of a contract vehicle?
Yes. 75N91024D00002 is part of PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ.
Was contract 75N91024D00002 competed?
The extent of competition for 75N91024D00002 was full and open competition. The government received 9 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV